Statin use prior to first myocardial infarction in contemporary patients: Inefficient and not gender equitable

Preventive Medicine

Volumn 83, Issue , 2016, Pages 63-69

  Kulenovic, Imra ^a   Mortensen, Martin Bødtker ^a   Bertelsen, Jette ^b   May, Ole ^c   Dodt, Karen Kaae ^d   Kanstrup, Helle ^a   Falk, Erling ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b RANDERS REGIONAL HOSPITAL   (Denmark)

^c HERNING HOSPITAL   (Denmark)

^d HORSENS REGIONAL HOSPITAL   (Denmark)

Author keywords

Cardiovascular disease; Gender; Myocardial infarction; Prevention; SCORE; Statin

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE ASSESSMENT; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DENMARK; DIABETES MELLITUS; DRUG USE; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SYSTEMATIC CORONARY RISK EVALUATION; SYSTOLIC BLOOD PRESSURE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRIMARY PREVENTION;

AGED; DENMARK; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRIMARY PREVENTION; RISK ASSESSMENT; SEX FACTORS;

EID: 84951729553     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2015.12.001     Document Type: Article

References (54)

1. Brekke M., Straand J. Does present use of cardiovascular medication reflect elevated cardiovascular risk scores estimated ten years ago? A population based longitudinal observational study. BMC Public Health 2011, 11:144. (Mar 2). 10.1186/1471-2458-11-144.
2. Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J., O'Connell R., et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015, 385:1397-1405.
3. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B., Emberson J., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:581-590.
4. Conroy R.M., Pyörälä K., Fitzgerald A.P., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J. 2003, 24:987-1003.
5. Cooney M.T., Dudina A., De Bacquer D., et al. SCORE Investigators. How much does HDL cholesterol add to risk estimation? A report from the SCORE Investigators. Eur. J. Cardiovasc. Prev. Rehabil. 2009, 16:304-314.
6. DeFilippis A.P., Young R., Carrubba C.J., et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann. Intern. Med. 2015, 162:266-275.
7. ESC HeartScore risk calculator http://www.heartscore.org.
8. Forster A.S., Dodhia H., Booth H., et al. Estimating the yield of NHS Health Checks in England: a population-based cohort study. J. Public Health (Oxf.) 2015 Jun, 37(2):234-240.
9. Fuster V. Are predictive risk scores useful?. Nat. Rev. Cardiol. 2009, 6:493.
10. Go Red For Women.American Heart Association https://www.goredforwomen.org/.
11. Goff D.C., Lloyd-Jones D.M., Bennett G., et al. ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014 2013, 129:S49-S73. (25 Suppl 2).
12. Graham I.M., Stewart M., Hertog M.G. Cardiovascular Round Table Task Force. Factors impeding the implementation of cardiovascular prevention guidelines: findings from a survey conducted by the European Society of Cardiology. Eur. J. Cardiovasc. Prev. Rehabil. 2006, 13:839-845.
13. Graversen L., Christensen B., Borch-Johnsen K., Lauritzen T., Sandbaek A. Lipid-lowering drugs as primary prevention in general practice: do patients reach guideline goals and continue treatment? ADDITION Denmark. Scand. J. Prim. Health Care 2011, 29:216-221.
14. Hobbs F.D., Jukema J.W., Da Silva P.M., McCormack T., Catapano A.L. Barriers to cardiovascular disease risk scoring and primary prevention in Europe. QJM 2010, 103:727-739.
15. Jameson J.L., Longo D.L. Precision medicine - personalized, problematic, and promising. N. Engl. J. Med. 2015, 372:2229-2234.
16. Jansen J., Bonner C., McKinn S., et al. General practitioners' use of absolute risk versus individual risk factors in cardiovascular disease prevention: an experimental study. BMJ Open 2014, 4. 10.1136/bmjopen-2014-004812.
17. JBS3 Board Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 2014, 100(Suppl. 2):ii1-ii67. (Apr). 10.1136/heartjnl-2014-305693.
18. Lim S.S., Vos T., Flaxman A.D., et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2224-2260.
19. Mancini G.B., Tashakkor A.Y., Baker S., et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can. J. Cardiol. 2013, 29:1553-1568.
20. Medstat-Denmark Sales of medicines in Denmark 1996-2013 Available on. http://www.medstat.dk.
21. Mortensen M.B., Falk E. Real-life evaluation of European and American high-risk strategies for primary prevention of cardiovascular disease in patients with first myocardial infarction. BMJ Open 2014 Oct 17, 4(10).
22. Mortensen M.B., Afzal S., Nordestgaard B.G., Falk E. The high-density lipoprotein-adjusted SCORE model worsens SCORE-based risk classification in a contemporary population of 30 824 Europeans: the Copenhagen General Population Study. Eur. Heart J. 2015, 36:2446-2453.
23. Mosca L., Benjamin E.J., Berra K., et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women - 2011 update: a guideline from the American Heart Association. Circulation 2011, 123:1243-1262.
24. Naci H., Brugts J.J., Fleurence R., Ades A.E. Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials. Eur. J. Prev. Cardiol. 2013, 20:658-670.
25. National Institute for Health andCare Excellence (NICE) Clinical Guideline CG181: Lipid modification - cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease 2014, National Clinical Guideline Centre, (July 2014. http://www.nice.org.uk/Guidance/cg181 (accessed 26 July 2014)).
26. Navar-Boggan A.M., Peterson E.D., D'Agostino R.B., Pencina M.J., Sniderman A.D. Using age- and sex-specific risk thresholds to guide statin therapy: one size may not fit all. J. Am. Coll. Cardiol. 2015, 65:1633-1639.
27. Nichols M., Townsend N., Luengo-Fernandez R., et al. European Cardiovascular Disease Statistics 2012 2012, European Heart Network and European Society of Cardiology, (Available at: http://www.escardio.org/static_file/Escardio/Press-media/press-releases/2013/EU-cardiovascular-disease-statistics-2012.pdf).
28. Nichols M., Townsend N., Scarborough P., Rayner M. Trends in age-specific coronary heart disease mortality in the European Union over three decades: 1980-2009. Eur. Heart J. 2013, 34:3017-3027.
29. Nichols M., Townsend N., Scarborough P., Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur. Heart J. 2014, 35:2950-2959.
30. Nordestgaard B.G., Adourian A.S., Freiberg J.J., Guo Y., Muntendam P., Falk E. Risk factors for near-term myocardial infarction in apparently healthy men and women. Clin. Chem. 2010, 56:559-567.
31. Oriol-Zerbe C., Abholz H.H. Primary prevention of cardiovascular diseases by lipid-lowering treatment in German general practice: results from GPs ignoring guidelines and risk calculators. Eur. J. Gen. Pract. 2007, 13:27-34.
32. Pandya A., Sy S., Cho S., Weinstein M.C., Gaziano T.A. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. JAMA 2015, 314:142-150.
33. Paulus J.K., Shah N.D., Kent D.M. All else being equal, men and women are still not the same: using risk models to understand gender disparities in care. Circ. Cardiovasc. Qual. Outcomes 2015, 8:317-320.
34. Perk J., De Backer G., Gohlke H., et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur. Heart J. 2012, 33:1635-1701.
35. Red Alert for Women's Hearts.European Heart Network http://www.ehnheart.org/publications/publications/publication/97--red-alert-for-womens-hearts.html.
36. Red Alert for Women's Hearts.European Society of Cardiology http://www.escardio.org/static_file/Escardio/EU-Affairs/WomensHearts-RedAlert.pdf.
37. Red Alert for Women's Hearts.World Heart Federation http://www.world-heart-federation.org/publications/heart-beat-e-newsletter/heart-beat-january-2010/in-this-issue/red-alert-on-womens-hearts/.
38. Ridker P.M., Buring J.E., Rifai N., et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds Risk Score. JAMA 2007, 297:611-619.
39. Selby K., Nanchen D., Auer R., et al. Low statin use in adults hospitalized with acute coronary syndrome. Prev. Med. 2015, 77:131-136.
40. Sibley C., Blumenthal R.S., Merz C.N., Mosca L. Limitations of current cardiovascular disease risk assessment strategies in women. J Womens Health (Larchmt) 2006, 15:54-56.
41. Stone N.J., Robinson J., Lichtenstein A.H., et al. ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014, 129:S1-S45. (25 Suppl 2).
42. Stramba-Badiale M., Fox K.M., Priori S.G., et al. MESA of cardiology. Eur. Heart J. 2006, 27:994-1005.
43. Svensson E., Nielsen R.B., Hasvold P., Aarskog P., Thomsen R.W. Statin prescription patterns, adherence, and attainment of cholesterol treatment goals in routine clinical care: a Danish population-based study. Clin. Epidemiol. 2015, 7:213-223.
44. Taylor F., Huffman M.D., Macedo A.F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev. 2013, 1. (Jan 31).
45. Thygesen K., Alpert J.S., White H.D. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur. Heart J. 2007, 28:2525-2538.
46. van Staa T.P., Smeeth L., Ng E.S., Goldacre B., Gulliford M. The efficiency of cardiovascular risk assessment: do the right patients get statin treatment?. Heart 2013, 99:1597-1602.
47. Virani S.S., Woodard L.D., Ramsey D.J., et al. Gender disparities in evidence-based statin therapy in patients with cardiovascular disease. Am. J. Cardiol. 2015, 115:21-26.
48. Wallach Kildemoes H., Vass M., Hendriksen C., Andersen M. Statin utilization according to indication and age: a Danish cohort study on changing prescribing and purchasing behaviour. Health Policy 2012, 108:216-227.
49. Wallach-Kildemoes H., Diderichsen F., Krasnik A., Lange T., Andersen M. Is the high-risk strategy to prevent cardiovascular disease equitable? A pharmacoepidemiological cohort study. BMC Public Health 2012, 12:610. (Aug 4). 10.1186/1471-2458-12-610.
50. Wallach-Kildemoes H., Andersen M., Diderichsen F., Lange T. Adherence to preventive statin therapy according to socioeconomic position. Eur. J. Clin. Pharmacol. 2013, 69:1553-1563.
51. Wenger N.K. Women and coronary heart disease: a century after Herrick: understudied, underdiagnosed, and undertreated. Circulation 2012, 126:604-611.
52. Wenger N.K. What if the FDA had launched its action plan to close the health disparities gap for women two decades earlier?. Trends Cardiovasc. Med. 2015, 25:95-97.
53. Women at Heart.European Society of Cardiology http://www.escardio.org/The-ESC/Initiatives/Women-at-heart/Women-at-Heart.
54. Wu J., Zhu S., Yao G.L., Mohammed M.A., Marshall T. Patient factors influencing the prescribing of lipid lowering drugs for primary prevention of cardiovascular disease in UK general practice: a national retrospective cohort study. PLoS One 2013, 8. 10.1371/journal.pone.0067611.